We are on track to accomplish all of our aims for this study. We were able to obtain the initial set of samples on April 26, 2018 so we had a short delay in starting this study. We have now completed all Year I study aims, with the exception of immunohistochemistry and FISH localization of Bartonella organisms within various cell types. An unanticipated complication arose that the mouse monoclonal antibody was no longer being made commercially. B. henselae specific FISH probes have been designed and validation of FISH probes are in-progress. IHC is also in- progress. All qPCR and ddPCR have been completed at this time and samples are waiting for FISH and IHC analysis.
Research Update End-year 1 CHF 02534: Clinical Trial for Evaluation of Propranolol and Doxorubicin in the Treatment of Canine Hemangiosarcoma
During the first year that the project has been active, we have made progress toward our objectives. The project goals have not been modified.
Our overall objective is to determine a clinically optimal dose and estimate the efficacy of propranolol in dogs with hemangiosarcoma when given as an adjunct to chemotherapy.
Research Update End-year 2 CHF 02519: Prevalence of Bartonella spp. Infection in Dogs with Cardiac and Splenic Hemangiosarcomas Within and Between Geographic Locations
Hemangiosarcoma (HSA) accounts for the majority of canine malignant splenic tumors and occurs in many large dog breeds, including mixed breeds. A less common site of HSA localization is the heart (cardiac HSA). Risk factors for both cardiac and splenic HSA remain unclear, confounding development of preventative strategies. The investigators recently reported a high prevalence of species of the bacterial genus Bartonella in dogs with HSA from North Carolina, suggesting a potential role in the initiation and/or progression of this cancer.
Research Update Mid-Year 1 CHF 02534: Clinical Trial for Evaluation of Propranolol and Doxorubicin in the Treatment of Canine Hemangiosarcoma
Update on clinical trial for hemangiosarcoma treatment from Dr. Dickerson.
Research Update Mid-Year-2 for CHF-02519: Prevelance of Bartonella Infection in Dogs with Cardiac and Splenic Hemangiosarcomas
Research update from Dr. Breitschwerdt looking at the potential role of the Tick-Borne bacterial infection, bartonella in the initiation and/or progression of hemangiosarcoma.
Research Update Mid-year 4 CHF 02234-MOU: A Novel Approach for Prevention of Canine Hemangiosarcoma
Research update from Dr. Modiano for Shine-On Hemangiosarcoma project looking into treatment of this disease.
Research Update End-Year 3 CHF-02234-MOU: A Novel Approach for Prevention of Canine Hemangiosarcoma
Research update from Dr. Modiano for Shine-On Hemangiosarcoma project looking into treatment of this disease.
Research Update Mid-Year-3 CHF-02234-MOU: A Novel Approach for Prevention of Canine Hemangiosarcoma
Research update from Dr. Modiano for Shine-On Hemangiosarcoma project looking into treatment of this disease.
Research Update End Year 2 CHF-02234-MOU: A Novel Approach for Prevention of Canine Hemangiosarcoma
Research update from Dr. Modiano for Shine-On Hemangiosarcoma project looking into treatment of this disease.
Research Update End-Year-1 for CHF-02519: Prevelance of Bartonella Infection in Dogs with Cardiac and Splenic Hemangiosarcomas
Research update from Dr. Breitschwerdt looking at the potential role of the Tick-Borne bacterial infection, bartonella in the initiation and/or progression of hemangiosarcoma.
